Mesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference
January 11, 2017 06:00 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO) (ASX:MSB) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference....
Mesoblast Receives A$29.6 Million Following Share Issue to Mallinckrodt
January 09, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$29.6 million (US$21.7 million) following...
Mesoblast and Mallinckrodt Enter Into Equity Purchase Agreement to Exclusively Negotiate Development and Commercialization of Mesoblast's Cell Therapy Products for Chronic Low Back Pain and Acute Graft Versus Host Disease
December 22, 2016 17:22 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into an equity purchase agreement with Mallinckrodt...
United States Congress Legislates New Accelerated Approval Pathway for Regenerative Advanced Therapies
December 09, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today welcomed the passage of a Bill approving the 21st Century Cures Act by the...
MD Anderson Cancer Center and National Institutes of Health to Fund Clinical Trial Combining Two Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients
December 06, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United...
Mesoblast Provides Corporate Update and Financial Results for the First Quarter Ended September 30, 2016
November 14, 2016 16:51 ET
|
Mesoblast Limited
MELBOURNE, Australia, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided a quarterly corporate update on its operational highlights, including its key...
Mesoblast Announces Successful Interim Futility Analysis In Phase 3 Trial For Acute Graft Versus Host Disease
November 14, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the Phase 3 trial of its intravenous product...
Mesoblast to Host First Quarter Financial Results Conference Call and Webcast
November 09, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first quarter ended...
Mesoblast Named 2016 Cell Therapy Company of the Year at Frost & Sullivan Asia Pacific Best Practices Awards
October 18, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it received the Frost & Sullivan Asia Pacific 2016 Cell...
Mesoblast Japan Strategy Highlighted at Australia-Japan Business Council Annual Meeting
October 12, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) yesterday gave a strategic update on its product commercialization plans in Japan....